Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies

Fig. 2

Overall survival rates in patients (a) with skeletal muscle loss (SML) or non-SML (P = 0.018), (b) with alpha-fetoprotein (AFP) < 20 ng/mL or ≥ 20 ng/mL (P <  0.001), and (c) with maximum tumor diameter <30 mm or ≥30 mm (P = 0.006). Survival rates were estimated with the Kaplan-Meier method and compared using log-rank tests

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us